Drug Profile

GT 002

Latest Information Update: 16 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lund University
Developer Gabather
Class Antipsychotics; Small molecules
Mechanism of Action GABA A receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Schizophrenia
Preclinical Cognition disorders; Unspecified

Most Recent Events

11 Apr 2024 Gabather and Centre for Neuropsychiatric Schizophrenia Research agree to initiate clinical trial of GT 002 for Schizophrenia
11 Apr 2024 Interim adverse events data from a phase I EEG/fMRI target engagement trial released by Gabather
11 Apr 2024 Gabather in collaboration with Centre for Neuropsychiatric Schizophrenia Research plans a phase II trial for Schizophrenia in Denmark

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com